The final, formatted version of the article will be published soon.
REVIEW article
Front. Med.
Sec. Precision Medicine
Volume 12 - 2025 |
doi: 10.3389/fmed.2025.1535682
This article is part of the Research Topic Nanomedicine Targeting Central Nervous System View all 3 articles
Recent advances in nanotechnology for Parkinson's disease: diagnosis, treatment, and future perspectives
Provisionally accepted
Virendra Kumar Yadav
1*
Seshathiri Dhanasekaran
2*
Nisha Choudhary
3
Deepak Nathiya
4
Vishal Thakur
5
Rachna Gupta
6
Sheersha Pramanik
7
Dr. Pankaj Kumar
8*
Nishant Gupta
9
Ashish Patel
3- 1 Marwadi University, Rajkot, Gujarat, India
- 2 UiT The Arctic University of Norway, Tromsø, Troms, Norway
- 3 Hemchandracharya North Gujarat University, Patan, Gujarat, India
- 4 NIMS University, Jaipur, Rajasthan, India
- 5 Chitkara Institute of Engineering & Technology, Chitkara University, Punjab, Punjab, India
- 6 National Institute of Pharmaceutical Education and Research, Ahmedabad, Ahmedabad, Gujarat, India
- 7 Indian Institute of Technology Madras, Chennai, Tamil Nadu, India
- 8 Parul University, Waghodia, India
- 9 River Engineering Pvt Ltd, Greater Noida, India
Parkinson's disease is a progressive neurodegenerative disease that destroys substantia nigra dopaminergic neurons, causing tremors, bradykinesia, rigidity, and postural instability. Current treatment approaches primarily focus on symptom management, employing pharmacological, nonpharmacological, and surgical methods. However, these treatments often result in fluctuating symptoms, side effects, and disease progression. Here, the authors have reviewed the emerging field of nanomedicine as a promising path for Parkinson's disease treatment, emphasizing its potential to overcome the limitations of traditional therapies. Nanomedicine utilizes nanoparticles for targeted drug delivery, leveraging their small size and high surface area to volume ratio to cross the bloodbrain barrier and deliver therapeutic agents directly to affected brain regions. Various nanoparticles, including lipid-based, polymeric, metallic, and carbon-based, have shown potential in Parkinson's disease treatment. Additionally, nanocarrier systems like liposomes, nanogels, dendrimers, and solid lipid nanoparticles offer controlled and sustained release of therapeutic agents, enhancing their bioavailability and reducing side effects. This review provides insights into the pathophysiology of Parkinson's disease, highlighting the mechanisms of neurodegeneration, the role of alpha-synuclein, and the disruption of dopaminergic pathways. It further discusses the application of gene therapy in conjunction with nanomedicine for targeted therapeutic interventions.
Keywords: CRISPR/Cas 9, dopaminergic pathways, Gallium nanoparticles, neurodegenerative, Neuroglia, parkinsons
Received: 27 Nov 2024; Accepted: 06 Jan 2025.
Copyright: © 2025 Yadav, Dhanasekaran, Choudhary, Nathiya, Thakur, Gupta, Pramanik, Kumar, Gupta and Patel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Virendra Kumar Yadav, Marwadi University, Rajkot, 360003, Gujarat, India
Seshathiri Dhanasekaran, UiT The Arctic University of Norway, Tromsø, 9019, Troms, Norway
Dr. Pankaj Kumar, Parul University, Waghodia, India
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.